Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CIV-21-06-036845 | Registry Identifier | EUDAMED |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of the study is to explore the convergent validity of smartphone-based Konectom DOAs against in-clinic standard assessments.
The secondary objectives of this study are to evaluate the test-retest reliability of smartphone-based Konectom Digital Outcome Assessments (DOAs); to determine the relationship between Konectom upper limb DOAs and conventional upper limb assessments in clinical environments; to determine the relationship between Konectom lower limb DOAs and status of ambulation in clinical environments; to evaluate group differences in smartphone-based Konectom DOAs [self-administered at home and in-clinic] between person with spinal muscular atrophy (PwSMA) and healthy subjects (HS); to evaluate the variability of Konectom DOAs self-administered in everyday environment in HS and PwSMA; to compare Konectom DOAs between in-clinic supervised administration versus self-assessments in everyday environment in HS, PwSMA groups; to evaluate the relationship of Konectom DOAs against patient-reported outcomes (PROs) in PwSMA and to evaluate the clinical safety of Konectom in PwSMA.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants with SMA (PwSMA) | Experimental | Participants with SMA will have their motor functions assessed using the Konectom NMD smartphone-based application up to Day 28. |
|
| Participants with ALS (PwALS) | Experimental | Participants with ALS will have their cognitive and motor functions assessed using the Konectom NMD smartphone-based application up to Day 28. As per protocol version 4.0, enrolment of ALS participants is stopped, and the data of the already enrolled ALS participants would not be analyzed. |
|
| Healthy Participants | Experimental | Healthy participants will have their cognitive and motor functions assessed using the Konectom NMD smartphone-based application for 28 days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Konectom NMD Application | Device | Administered as specified in the treatment arm. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Type of Correlation of Konectom DOAs Versus Hammersmith Functional Motor Scale-Expanded (HFMSE) Total Score in PwSMA | This outcome measure will assess the convergent validity of smartphone-based Konectom DOAs against in-clinic standard assessments. | Up to 28 days |
| Strength of Correlation of Konectom DOAs Versus HFMSE Total Score in PwSMA | This outcome measure will assess the convergent validity of smartphone-based Konectom DOAs against in-clinic standard assessments. | Up to 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| Interclass Correlation Coefficient (ICC) of the Konectom Digital Outcome Assessment (DOA) Scores | This outcome measure will assess test-retest reliability of smartphone-based Konectom DOAs. | Up to 28 days |
| Type of Correlation of Upper Limb Konectom DOAs Versus Revised Upper Limb Module (RULM) in PwSMA |
Not provided
Key Inclusion Criteria:
For PwSMA
For Healthy Participants
Key Exclusion Criteria:
For PwSMA
NOTE: Other protocol defined inclusion/ exclusion criteria may apply.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Biogen | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Essen | North Rhine-Westphalia | 45147 | Germany | ||
| Research Site |
In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009134 | Muscular Atrophy, Spinal |
| D009468 | Neuromuscular Diseases |
| ID | Term |
|---|---|
| D013118 | Spinal Cord Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D016472 | Motor Neuron Disease |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This outcome measure will assess the relationship between Konectom Upper Limb DOAs and conventional upper limb assessments in clinical environments. |
| Up to 28 days |
| Strength of Correlation of Upper Limb Konectom DOAs Versus RULM in PwSMA | This outcome measure will assess the relationship between Konectom Upper Limb DOAs and conventional upper limb assessments in clinical environments. | Up to 28 days |
| Type of Correlation of Upper Limb Konectom DOAs Versus 9-Hole Peg test (9HPT) in PwSMA | This outcome measure will assess the relationship between Konectom Upper Limb DOAs and conventional upper limb assessments in clinical environments. | Up to 28 days |
| Strength of Correlation of Upper Limb Konectom DOAs Versus 9HPT in PwSMA | This outcome measure will assess the relationship between Konectom Upper Limb DOAs and conventional upper limb assessments in clinical environments. | Up to 28 days |
| Type of Correlation of Lower Limb Konectom DOAs Versus 6-Minute Walk Test (MWT) Total Distance in Ambulatory PwSMA | This outcome measure will assess the relationship between Konectom Lower Limb DOAs and status of ambulation in clinical environments. | Up to 28 days |
| Strength of Correlation of Lower Limb Konectom DOAs Versus 6-MWT Total Distance in Ambulatory PwSMA | This outcome measure will assess the relationship between Konectom Lower Limb DOAs and status of ambulation in clinical environments. | Up to 28 days |
| Differences Between PwSMA and HS in the Konectom DOA Scores During Each Testing Condition | This outcome measure will assess the group differences in smartphone-based Konectom DOAs [self-administered at home and in-clinic] between PwSMA and healthy subjects (HS). | Up to 28 days |
| Standard Deviation of Each Participant's Raw Konectom DOA Scores Over the At-Home Period | This outcome measure will assess the variability of Konectom DOAs self-administered in everyday environment in HS and PwSMA. | Up to 28 days |
| Paired-Comparisons of Konectom DOA Scores Between In-Clinic Supervised Administration and Self-Assessment In Everyday Environment, Separately for HS and PwSMA Groups | This outcome measure will assess the comparison of Konectom DOAs between in-clinic supervised administration versus self-assessments in everyday environment in HS and PwSMA groups. | Up to 28 days |
| Type of Correlation of Konectom DOA Scores Versus Neuro-Quality of Life (QoL) Total Scores in PwSMA | This outcome measure will assess the relationship of Konectom DOAs against patient-reported outcomes (PROs) in PwSMA. | Up to 28 days |
| Strength of Correlation of Konectom DOA Scores Versus Neuro-QoL Total Scores in PwSMA | This outcome measure will assess the relationship of Konectom DOAs against PROs in PwSMA. | Up to 28 days |
| Type of Correlation of Konectom DOA Scores Versus Fatigue Severity Scale (FSS) Total Scores in PwSMA | This outcome measure will assess the relationship of Konectom DOAs against PROs in PwSMA. | Up to 28 days |
| Strength of Correlation of Konectom DOA Scores Versus FSS Total Scores in PwSMA | This outcome measure will assess the relationship of Konectom DOAs against PROs in PwSMA. | Up to 28 days |
| Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) Related to Konectom NMD Use | An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, in the view of the Investigator, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a birth defect. This outcome measure will assess the clinical safety of Konectom NMD in PwSMA. | Up to 43 days |
| Dresden |
| 01307 |
| Germany |
| Research Site | Hanover | 30625 | Germany |
| Research Site | Heidelberg | 69120 | Germany |
| LMU Klinikum Friedrich-Baur-Institute, Dept. of Neurology | Munich | 80336 | Germany |
| D019636 | Neurodegenerative Diseases |